Skip to main content

Table 3 Comorbidities present in more than 5% of patients at study start

From: Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)

Comorbidities

Patients, n (%) (n = 396)

Depression

53 (13.4)

Hypertension

34 (8.6)

Obesity

29 (7.3)

Anxiety

28 (7.1)

Somnolence

27 (6.8)

Blood prolactin increased

21 (5.3)

Extrapyramidal disorder

21 (5.3)

Weight increased

20 (5.1)